solutions phase-ii-iv Clinical Development Related Topics 
Pharmaceutical Technology
MARCH 1, 2023
After almost seven years of research and advancement post-initial approval, ASO therapies now represent over 50% of all RNA-based therapeutics in clinical development, according to GlobalData’s pipeline product database, and may emerge as improved and highly disruptive next-generation RNA therapies.
XTalks
MAY 19, 2023
This article delves into ten trends and statistics in the world of clinical trials for 2023. And don’t forget to explore the upcoming webinars about clinical trials on Xtalks to see what piques your curiosity about the latest clinical trial solutions. percent, 81.1 percent, 84.9 percent and 87.2 percent.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
SEPTEMBER 16, 2020
New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers. New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Sign up here for the session on Saturday, 19 September, 16:00-16:30 CEST.
The Pharma Data
JANUARY 20, 2021
CytomX expects to use any remaining net proceeds from this offering for capital expenditures, working capital and other general corporate purposes. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to these securities may also be obtained for free from: J.P.
The Pharma Data
AUGUST 22, 2021
Two formulations were approved, a tablet and a new oral solution (weight-based dosing). The polyarticular JIA and juvenile PsA approval is based on data from a Phase 3 pivotal study in patients with polyarticular JIA as well as other JIA subtypes, including juvenile PsA. About the JIA Study.
XTalks
AUGUST 2, 2023
5) ProQuad/M-M-R II/Varivax ProQuad, M-M-R II and Varivax are all measles, mumps, rubella and varicella vaccines indicated for different age groups. M-M-R II was approved even earlier, in 1978. The private sector costs/dose of pediatric versions of M-M-R II, ProQuad and Varivax are $89.87, $262.37 billion in 2022.
Pfizer
NOVEMBER 2, 2022
Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. About the Phase 1 Study . Wed, 11/02/2022 - 15:44.
Expert insights. Personalized for you.
147 
Let's personalize your content